Physician profile
Greg Booth
NPI 1063674174
$3,785.28
in general payments reported to CMS, 2019-2025
30 companies · $925 in 2025
The $925 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $503 · 2020: $587 · 2021: $339 · 2022: $191 · 2023: $345 · 2024: $896 · 2025: $925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,165.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $754.08 | 2019-2025 | Breztri, Farxiga |
| Abbvie INC. | $622.42 | 2021-2025 | Ubrelvy, Qulipta, Synthroid |
| Pfizer INC. | $456.42 | 2019-2025 | |
| Lilly USA, LLC | $364.88 | 2020-2025 | Zepbound, Mounjaro, Kisunla |
| Novo Nordisk INC | $337.16 | 2020-2025 | Ozempic, Rybelsus |
| Amgen INC. | $149.16 | 2020-2025 | Krystexxa, Repatha, Otezla |
| Exact Sciences Corporation | $124.34 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $107.46 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Allergan, INC. | $103.96 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $99.22 | 2020-2024 | Vaxelis, Gardasil, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.04 | 2024-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $85.29 | 2019-2021 | |
| Astellas Pharma US INC | $61.60 | 2020-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.12 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.38 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $54.57 | 2022 | |
| Alnylam Pharmaceuticals INC. | $33.48 | 2020 | |
| Sumitomo Pharma America, INC. | $29.92 | 2024 | Gemtesa |
| Axsome Therapeutics, INC. | $25.37 | 2025 | Auvelity |
| Aimmune Therapeutics, INC. | $24.89 | 2025 | Zenpep |
| Collegium Pharmaceutical, INC. | $19.95 | 2025 | Jornay Pm |
| Abbott Laboratories | $19.00 | 2024 | Eterna |
| Seqirus USA INC | $17.56 | 2025 | Flucelvax, Fluad |
| Medtronic, INC. | $15.48 | 2022 | |
| Cranial Technologies, INC | $15.34 | 2021 | |
| Phathom Pharmaceuticals, INC. | $15.31 | 2025 | Voquezna |
| Amryt Pharma Holdings Ltd | $14.19 | 2021 | |
| Eisai INC. | $13.09 | 2020 | |
| Medtronic Vascular, INC. | $12.37 | 2019 | |
| Jazz Pharmaceuticals INC. | $11.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Greg Booth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.